Compare BVS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BVS | GERN |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.2M | 911.0M |
| IPO Year | 2016 | 1996 |
| Metric | BVS | GERN |
|---|---|---|
| Price | $14.38 | $1.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.00 | $2.17 |
| AVG Volume (30 Days) | 810.2K | ★ 10.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.46 | 51.85 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $568,087,000.00 | $1,065,000.00 |
| Revenue This Year | $7.52 | $26.91 |
| Revenue Next Year | $7.06 | $43.75 |
| P/E Ratio | $27.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.26 | $1.04 |
| 52 Week High | $15.89 | $2.01 |
| Indicator | BVS | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 52.18 |
| Support Level | $7.29 | $1.42 |
| Resistance Level | $15.89 | $1.68 |
| Average True Range (ATR) | 0.78 | 0.10 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 51.67 | 58.82 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.